Home News Insights Trading halts Paper trading Guide Community My account

Market calendarChecking market schedule

Display in USD

Loading news article.

About WAPE
U.S. stock guide
Scanner guide
Paper trading guide
Terms of service
Privacy policy
Announcements
FAQ

Support: help@wapeb.comPartnerships: partnership@wapeb.com

WAPE is a free research, analysis and paper trading service. It does not place real securities orders. Market data and AI summaries are for information only, not investment advice or stock recommendations. Information may include delays, errors or estimates. Check original sources and supporting materials. You are responsible for your investment decisions and any resulting gains or losses.

Language한국어 English

Loading news article.

Milestone Pharmaceuticals Announces Positive Data for CARDAMYST in Post-Ablation PSVT Patients | WAPE

Back All news

Newsfiscal.ai

Milestone Pharmaceuticals Announces Positive Data for CARDAMYST in Post-Ablation PSVT Patients

Nov 3, 2026, 09:04 ET · Published

View source

Article summary

Milestone Pharmaceuticals reported that CARDAMYST (etripamil) nasal spray successfully converted approximately two-thirds of patients with recurrent symptomatic PSVT after prior catheter ablation to normal heart rhythm within 30 minutes.

An excerpt from the original article.

Related companies

Milestone Pharmaceuticals Inc. Common SharesMISTView stock

Milestone Pharmaceuticals Announces Positive Data for CARDAMYST in Post-Ablation PSVT Patients

Article summary

Related companies

Analyzed by WAPE AI.

Comments —